DDInter1042 DDInter669
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Ertugliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Ertugliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cinoxacin
Ertugliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Ertugliflozin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Ertugliflozin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ertugliflozin may lead to a major life threatening interaction when taken with Gatifloxacin